Medifast, Inc.(MED)Earnings, Financials & Key Ratios

MED•NYSE

Price updated Jun 19, 2026

SectorConsumer Cyclical IndustryPersonal Services Sub-IndustryHealth, Fitness and Wellness Services

AboutMedifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.Show more

Revenue$386M-36.0%
EBITDA-$4M-123.8%
Net Income-$19M-993.0%
EPS (Diluted)-1.70-994.7%
Gross Margin71.33%-3.3%
EBITDA Margin-0.96%-137.2%
Operating Margin-3.68%-871.2%
Net Margin-4.84%-1494.4%
ROE-9.13%-998.5%

MED Key Insights

Medifast, Inc. (MED) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Good 3Y average ROE of 15.9%
✓Trading at only 0.6x book value
✓Efficient asset utilization: 1.5x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Sales declining 16.2% over 5 years

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when MED posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

MED Price & Volume

Medifast, Inc. (MED) stock price & volume — 10-year historical chart

Loading chart...

MED Growth Metrics

Medifast, Inc. (MED) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years3.53%

5 Years-16.22%

3 Years-37.74%

TTM-36.31%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-186.19%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-181.54%

Return on Capital

10 Years56.77%

5 Years52.12%

3 Years19.7%

Last Year-6.55%

MED Recent Earnings

Medifast, Inc. (MED) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 11/12 qtrs (92%)

Q2 2026Latest

May 4, 2026

Metric

Actual

Est

EPS

$0.19+65.5%

$0.55

Rev

$76M+9.9%

$69M

Q1 2026

Feb 17, 2026

Metric

Actual

Est

EPS

$0.55+27.6%

$0.76

Rev

$75M+5.2%

$71M

Q4 2025

Nov 3, 2025

Metric

Actual

Est

EPS

$0.21-2000.0%

$0.01

Rev

$89M+25.2%

$71M

Q3 2025

Aug 4, 2025

Metric

Actual

Est

EPS

$0.04+113.3%

$0.30

Rev

$106M+12.5%

$94M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 4, 2026	$0.19vs $0.55+65.5%	$76Mvs $69M+9.9%
Q1 2026	Feb 17, 2026	$0.55vs $0.76+27.6%	$75Mvs $71M+5.2%
Q4 2025	Nov 3, 2025	$0.21vs $0.01-2000.0%	$89Mvs $71M+25.2%
Q3 2025	Aug 4, 2025	$0.04vs $0.30+113.3%	$106Mvs $94M+12.5%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
HIMSHims & Hers Health, Inc.Direct Competitor	7.79B	35.47	69.55	59%	-0.56%	-2.48%	2.34
NUSNu Skin Enterprises, Inc.Direct Competitor	243.72M	5.02	1.58	-14.26%	3.78%	6.84%	0.45
USNAUSANA Health Sciences, Inc.Direct Competitor	348.47M	18.88	32.55	8.28%	1.16%	1.84%	0.02
RVLVRevolve Group, Inc.Direct Competitor	1.55B	21.79	25.34	8.48%	5.05%	12.84%	0.06
WWWW International, Inc.Direct Competitor	191.98M	19.20	0.18	-9.58%	155.5%	334.45%	1.47
HLFHerbalife Nutrition Ltd.Product Competitor	1.23B	11.90	5.41	0.89%	4.67%
PLNTPlanet Fitness, Inc.Product Competitor	4.21B	52.98	20.22	12.06%	16.52%
XPOFXponential Fitness, Inc.Product Competitor	254.84M	6.83	-4.65	-1.71%	-11.1%

Compare MED vs Peers

Medifast, Inc. (MED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HIMS

Most directly comparable listed peer for MED.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare MED against a more recognizable public peer.

Peer Set

Compare Top 5

vs HIMS, NUS, USNA, RVLV

MED Income Statement

Medifast, Inc. (MED) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Metric	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	301.56M	501M	713.67M	934.84M	1.53B	1.6B	1.07B	602.46M	385.79M	346.1M
Revenue Growth %	9.85%	66.14%	42.45%	30.99%	63.25%	4.75%	-32.94%	-43.8%	-35.96%	-36.31%
Cost of Goods Sold	73.75M	121.1M	176.81M	237.03M	398.49M	458.16M	296.2M	157.84M	110.6M	103.41M
COGS % of Revenue	24.46%	24.17%	24.78%	25.35%	26.11%	28.66%	27.63%	26.2%	28.67%	-
Gross Profit	227.81M▲ 0%	379.9M▲ 66.8%	536.86M▲ 41.3%	697.82M▲ 30.0%	1.13B▲ 61.6%	1.14B▲ 1.1%	775.85M▼ 32.0%	444.62M▼ 42.7%	275.19M▼ 38.1%	242.7M▲ 0%
Gross Margin %	75.54%	75.83%	75.22%	74.65%	73.89%	71.34%	72.37%	73.8%	71.33%	70.12%
Gross Profit Growth %	10.77%	66.76%	41.32%	29.98%	61.59%	1.14%	-31.97%	-42.69%	-38.11%	-
Operating Expenses	188.18M	310.84M	445.82M	563.66M	911.36M	955.61M	649.45M	441.75M	289.4M	258.94M
OpEx % of Revenue	62.4%	62.04%	62.47%	60.29%	59.72%	59.78%	60.58%	73.32%	75.02%	-
Selling, General & Admin	188.18M	310.84M	445.82M	563.66M	911.36M	955.61M	649.45M	441.75M	289.4M	258.94M
SG&A % of Revenue	62.4%	62.04%	62.47%	60.29%	59.72%	59.78%	60.58%	73.32%	75.02%	-
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income	39.63M▲ 0%	69.06M▲ 74.3%	91.04M▲ 31.8%	134.16M▲ 47.4%	216.24M▲ 61.2%	184.81M▼ 14.5%	126.4M▼ 31.6%	2.88M▼ 97.7%	-14.21M▼ 593.8%	-16.25M▲ 0%
Operating Margin %	13.14%	13.78%	12.76%	14.35%	14.17%	11.56%	11.79%	0.48%	-3.68%	-4.69%
Operating Income Growth %	47.56%	74.26%	31.82%	47.36%	61.18%	-14.54%	-31.6%	-97.72%	-593.85%	-
EBITDA	43.84M	73.5M	95.66M	138.47M	223.05M	195.79M	139.51M	15.59M	-3.71M	-5.28M
EBITDA Margin %	14.54%	14.67%	13.4%	14.81%	14.62%	12.25%	13.01%	2.59%	-0.96%	-1.53%
EBITDA Growth %	35.88%	67.65%	30.16%	44.75%	61.08%	-12.22%	-28.74%	-88.83%	-123.82%	-182.51%
D&A (Non-Cash Add-back)	4.21M	4.43M	4.62M	4.32M	6.81M	10.98M	13.11M	12.71M	10.5M	10.96M
EBIT	39.63M	69.06M	91.04M	134.16M	216.24M	184.76M	126.4M	2.88M	-14.21M	-11.53M
Net Interest Income	558K	1.31M	1.29M	246K	0	-701K	2.49M	4.8M	5.52M	4.21M
Interest Income	558K	1.31M	1.29M	246K	0	0	2.49M	4.8M	5.52M	5.59M
Interest Expense	0	0	0	0	0	701K	0	0	0	0
Other Income/Expense	694K	1.49M	1.32M	106K	-112K	-747K	2.4M	909K	8.57M	8.14M
Pretax Income	40.33M▲ 0%	70.55M▲ 74.9%	92.36M▲ 30.9%	134.26M▲ 45.4%	216.13M▲ 61.0%	184.06M▼ 14.8%	128.8M▼ 30.0%	3.79M▼ 97.1%	-5.64M▼ 248.9%	-8.11M▲ 0%
Pretax Margin %	13.37%	14.08%	12.94%	14.36%	14.16%	11.51%	12.01%	0.63%	-1.46%	-2.34%
Income Tax	12.61M	14.76M	14.45M	31.41M	52.1M	40.49M	29.38M	1.7M	13.03M	11.92M
Effective Tax Rate %	31.26%	20.92%	15.64%	23.39%	24.11%	22%	22.81%	44.78%	-231.12%	-147.03%
Net Income	27.72M▲ 0%	55.79M▲ 101.3%	77.92M▲ 39.7%	102.86M▲ 32.0%	164.03M▲ 59.5%	143.57M▼ 12.5%	99.42M▼ 30.8%	2.09M▼ 97.9%	-18.67M▼ 993.0%	-20.02M▲ 0%
Net Margin %	9.19%	11.14%	10.92%	11%	10.75%	8.98%	9.27%	0.35%	-4.84%	-5.79%
Net Income Growth %	55.43%	101.25%	39.66%	32.01%	59.47%	-12.48%	-30.75%	-97.9%	-992.97%	-186.19%
Net Income (Continuing)	27.72M	55.79M	77.92M	102.86M	164.03M	143.57M	99.42M	2.09M	-18.67M	-20.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	2.29▲ 0%	4.62▲ 101.7%	6.43▲ 39.2%	8.68▲ 35.0%	13.89▲ 60.0%	12.73▼ 8.4%	9.10▼ 28.5%	0.19▼ 97.9%	-1.70▼ 994.7%	-1.82▲ 0%
EPS Growth %	53.69%	101.75%	39.18%	34.99%	60.02%	-8.35%	-28.52%	-97.91%	-994.74%	-181.54%
EPS (Basic)	2.32	4.67	6.62	8.74	14.01	12.82	9.10	0.19	-1.70	-
Diluted Shares Outstanding	12.09M	12.08M	12.12M	11.85M	11.81M	11.28M	10.92M	10.96M	10.98M	11.01M
Basic Shares Outstanding	11.92M	11.95M	11.77M	11.77M	11.71M	11.2M	10.88M	10.93M	10.98M	11.01M
Dividend Payout Ratio	55.52%	41.51%	45.43%	51.71%	38.93%	49.89%	73.45%	34.19%	-	-

MED Balance Sheet

Medifast, Inc. (MED) balance sheet — assets, liabilities & shareholders' equity

Metric	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	125.2M	145.52M	154.15M	234.31M	306.87M	222.78M	224.03M	214.4M	201.68M	202.63M
Cash & Short-Term Investments	98.83M	101.03M	92.68M	174.47M	109.54M	87.69M	150.04M	162.34M	167.27M	71.53M
Cash Only	75.08M	81.36M	76.97M	163.72M	104.18M	87.69M	94.44M	90.93M	89.3M	71.53M
Short-Term Investments	23.76M	19.67M	15.7M	10.75M	5.36M	0	55.6M	71.42M	77.97M	0
Accounts Receivable	576K	1.01M	1.44M	584K	0	0	0	0	0	0
Days Sales Outstanding	0.7	0.74	0.73	0.23	-	-	-	-	-	-
Inventory	19.33M	38.89M	48.77M	53.39M	180.04M	118.86M	54.59M	42.42M	20.23M	21.4M
Days Inventory Outstanding	95.66	117.21	100.68	82.22	164.91	94.69	67.27	98.1	66.76	83.87
Other Current Assets	0	0	0	-584K	16.33M	16.24M	0	0	9.07M	109.7M
Total Non-Current Assets	20.73M	23.91M	40.5M	41.77M	91.46M	93.43M	85.88M	69.81M	55.33M	49.42M
Property, Plant & Equipment	18.61M	19.75M	38.84M	38.14M	80.59M	75.64M	67.11M	48.68M	38.46M	42.56M
Fixed Asset Turnover	16.20x	25.37x	18.37x	24.51x	18.94x	21.13x	15.97x	12.38x	10.03x	8.35x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.12M	1.18M	353K	2.94M	6.47M	12.46M	14.65M	9.67M	7.83M	6.85M
Total Assets	145.93M▲ 0%	169.43M▲ 16.1%	194.65M▲ 14.9%	276.08M▲ 41.8%	398.33M▲ 44.3%	316.21M▼ 20.6%	309.91M▼ 2.0%	284.21M▼ 8.3%	257.01M▼ 9.6%	252.05M▲ 0%
Asset Turnover	2.07x	2.96x	3.67x	3.39x	3.83x	5.06x	3.46x	2.12x	1.50x	1.32x
Asset Growth %	20.39%	16.1%	14.89%	41.83%	44.28%	-20.61%	-1.99%	-8.29%	-9.57%	-35.71%
Total Current Liabilities	37.14M	60.32M	79.39M	111.35M	169.83M	140.89M	92.3M	64.16M	42.96M	42.18M
Accounts Payable	13.8M	19.02M	22.61M	36.09M	70.89M	53.12M	39.19M	23.05M	15.07M	0
Days Payables Outstanding	68.28	57.32	46.67	55.58	64.94	42.32	48.3	53.3	49.72	105.77
Short-Term Debt	0	0	0	0	0	0	0	0	4.6M	3.92M
Deferred Revenue (Current)	0	0	4.33M	7.61M	8.05M	7.36M	574K	316K	384K	0
Other Current Liabilities	0	19.76M	0	0	0	0	0	32.77M	13.63M	38.26M
Current Ratio	3.37x	2.41x	1.94x	2.10x	1.81x	1.58x	2.43x	3.34x	4.69x	4.80x
Quick Ratio	2.85x	1.77x	1.33x	1.62x	0.75x	0.74x	1.84x	2.68x	4.22x	4.30x
Cash Conversion Cycle	28.07	60.63	54.74	26.87	-	-	-	-	-	-21.91
Total Non-Current Liabilities	208K	1.97M	10.43M	7.49M	26.02M	20.27M	16.13M	9.94M	15.13M	12.18M
Long-Term Debt	0	0	0	0	0	0	0	0	6.09M	12.18M
Capital Lease Obligations	0	0	10.43M	7.49M	26.02M	20.27M	16.13M	9.94M	6.09M	20.02M
Deferred Tax Liabilities	208K	1.97M	0	0	0	0	0	0	9.04M	9.04M
Other Non-Current Liabilities	0	-1.97M	0	0	0	0	0	0	-6.09M	0
Total Liabilities	37.35M	60.32M	89.82M	118.84M	195.85M	161.17M	108.43M	74.1M	58.09M	54.37M
Total Debt	0	0	13.6M	11.16M	32.54M	26.05M	22.01M	16.13M	16.79M	16.1M
Net Debt	-75.08M	-81.36M	-63.37M	-152.56M	-71.64M	-61.64M	-72.43M	-74.8M	-72.52M	-55.43M
Debt / Equity	-	-	0.13x	0.07x	0.16x	0.17x	0.11x	0.08x	0.08x	0.08x
Debt / EBITDA	-	-	0.14x	0.08x	0.15x	0.13x	0.16x	1.03x	-	-3.05x
Net Debt / EBITDA	-1.71x	-1.11x	-0.66x	-1.10x	-0.32x	-0.31x	-0.52x	-4.80x	-	10.49x
Interest Coverage	-	-	-	-	-	263.57x	-	-	-	-
Total Equity	108.58M▲ 0%	109.11M▲ 0.5%	104.83M▼ 3.9%	157.25M▲ 50.0%	202.47M▲ 28.8%	155.04M▼ 23.4%	201.48M▲ 30.0%	210.11M▲ 4.3%	198.92M▼ 5.3%	197.68M▲ 0%
Equity Growth %	13.09%	0.48%	-3.92%	50%	28.76%	-23.43%	29.95%	4.28%	-5.33%	-2.84%
Book Value per Share	8.98	9.03	8.65	13.27	17.14	13.75	18.45	19.17	18.11	17.96
Total Shareholders' Equity	108.58M	109.11M	104.83M	157.25M	202.47M	155.04M	201.48M	210.11M	198.92M	197.68M
Common Stock	12K	12K	12K	12K	12K	11K	11K	11K	11K	0
Retained Earnings	103.76M	131.34M	168.79M	154.35M	190.33M	139.85M	174.65M	176.78M	158.27M	156.15M
Treasury Stock	0	-30.88M	-63.99M	-5M	0	-6.4M	0	0	0	0
Accumulated OCI	-160K	-173K	25K	41K	111K	24K	248K	180K	234K	33K
Minority Interest	0	0	0	0	0	0	0	0	0	0

MED Cash Flow Statement

Medifast, Inc. (MED) cash flow — operating, investing & free cash flow history

Metric	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	43.24M	60.82M	84.26M	145.2M	94.55M	194.57M	147.66M	24.48M	6.86M	3.72M
Operating CF Margin %	14.34%	12.14%	11.81%	15.53%	6.2%	12.17%	13.77%	4.06%	1.78%	-
Operating CF Growth %	70.56%	40.66%	38.55%	72.32%	-34.88%	105.8%	-24.11%	-83.42%	-71.96%	-191.38%
Net Income	27.72M	55.79M	77.92M	102.86M	164.03M	143.57M	99.42M	2.09M	-18.67M	-20.02M
Depreciation & Amortization	4.21M	4.43M	4.62M	4.32M	6.81M	10.98M	13.11M	17.4M	14.24M	14.45M
Stock-Based Compensation	4.27M	3.12M	4.52M	6.8M	9.9M	11.05M	8.19M	7.36M	7.64M	3.54M
Deferred Taxes	-623K	-2.69M	1.6M	601K	-3.71M	-924K	1.21M	-7.4M	11.46M	11.44M
Other Non-Cash Items	879K	622K	3.1M	3.72M	5.16M	8.24M	5.46M	14.77M	2M	4.27M
Working Capital Changes	6.78M	-467K	-7.49M	26.9M	-87.65M	21.65M	20.28M	-9.74M	-9.8M	-9.95M
Change in Receivables	815K	122K	-4.06M	297K	0	0	0	0	0	0
Change in Inventory	-1.02M	-18.66M	-9.88M	-4.62M	-126.65M	61.19M	64.27M	12.17M	22.19M	17.96M
Change in Payables	8.01M	15.8M	0	0	0	-37.59M	-35.71M	-34.99M	-23.91M	-19.36M
Cash from Investing	-3.16M	-1.2M	-6.33M	-1.28M	-29.06M	-11.41M	-61.05M	-26.52M	-7.93M	-23.01M
Capital Expenditures	-3.24M	-4.94M	-10.06M	-5.89M	-34.21M	-16.68M	-6.48M	-7.45M	-5.61M	-5.19M
CapEx % of Revenue	1.08%	0.99%	1.41%	0.63%	2.24%	1.04%	0.6%	1.24%	1.46%	1.5%
Acquisitions	81K	196K	0	0	0	0	0	0	0	3.64M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	81K	196K	0	0	0	0	0	95K	3.31M	0
Cash from Financing	-17.36M	-53.33M	-82.32M	-57.14M	-125.13M	-199.58M	-79.79M	-1.51M	-564K	-902K
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	-2.54M	-30.71M	-47.21M	-5.55M	-62.09M	-127.96M	-6.96M	-836K	-369K	-814K
Dividends Paid	-15.39M	-23.16M	-35.4M	-53.19M	-63.86M	-71.62M	-73.02M	-715K	-195K	-88K
Share Repurchases	-2.54M	-30.71M	-47.21M	-5.55M	-62.09M	-127.96M	-6.96M	-836K	-369K	-814K
Other Financing	568K	547K	278K	1.6M	811K	0	188K	36K	0	0
Net Change in Cash	22.64M▲ 0%	6.29M▼ 72.2%	-4.39M▼ 169.8%	86.75M▲ 2076.1%	-59.54M▼ 168.6%	-16.49M▲ 72.3%	6.75M▲ 140.9%	-3.51M▼ 152.0%	-1.63M▲ 53.7%	-20.19M▲ 0%
Free Cash Flow	39.99M▲ 0%	55.88M▲ 39.7%	74.2M▲ 32.8%	139.31M▲ 87.7%	60.34M▼ 56.7%	177.89M▲ 194.8%	141.17M▼ 20.6%	17.02M▼ 87.9%	1.25M▼ 92.7%	-1.47M▲ 0%
FCF Margin %	13.26%	11.15%	10.4%	14.9%	3.95%	11.13%	13.17%	2.83%	0.32%	-0.43%
FCF Growth %	77.96%	39.71%	32.8%	87.74%	-56.69%	194.83%	-20.64%	-87.94%	-92.66%	-110.92%
FCF per Share	3.31	4.63	6.12	11.76	5.11	15.78	12.93	1.55	0.11	-0.13
FCF Conversion (FCF/Net Income)	1.56x	1.09x	1.08x	1.41x	0.58x	1.36x	1.49x	11.71x	-0.37x	0.07x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	13.62M	14.61M	17.31M	24.64M	56.76M	37.21M	34.26M	0	0	7.1M

MED Key Ratios

Medifast, Inc. (MED) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	27.1%	51.26%	72.84%	78.5%	91.2%	80.31%	55.77%	1.02%	-9.13%	-9.68%
Return on Invested Capital (ROIC)	76.35%	169.14%	197.34%	436.12%	239.35%	123.62%	85.23%	1.63%	-8.15%	-9.31%
Gross Margin	75.54%	75.83%	75.22%	74.65%	73.89%	71.34%	72.37%	73.8%	71.33%	70.12%
Net Margin	9.19%	11.14%	10.92%	11%	10.75%	8.98%	9.27%	0.35%	-4.84%	-5.79%
Debt / Equity	-	-	0.13x	0.07x	0.16x	0.17x	0.11x	0.08x	0.08x	0.08x
Interest Coverage	-	-	-	-	-	263.57x	-	-	-	-
FCF Conversion	1.56x	1.09x	1.08x	1.41x	0.58x	1.36x	1.49x	11.71x	-0.37x	0.07x
Revenue Growth	9.85%	66.14%	42.45%	30.99%	63.25%	4.75%	-32.94%	-43.8%	-35.96%	-36.31%

MED SEC Filings & Documents

Medifast, Inc. (MED) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 4, 2026·SEC

Material company update

Mar 20, 2026·SEC

Material company update

Feb 17, 2026·SEC

10-K Annual Reports

FY 2026

Feb 17, 2026·SEC

FY 2025

Feb 18, 2025·SEC

FY 2024

Feb 20, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 4, 2026·SEC

FY 2025

Nov 3, 2025·SEC

FY 2025

Aug 4, 2025·SEC

MED Frequently Asked Questions

Medifast, Inc. (MED) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Medifast, Inc. (MED) reported $346.1M in revenue for fiscal year 2025. This represents a 1997% increase from $16.5M in 1996.

Medifast, Inc. (MED) saw revenue decline by 36.0% over the past year.

Medifast, Inc. (MED) reported a net loss of $20.0M for fiscal year 2025.

Dividend & Returns

Yes, Medifast, Inc. (MED) pays a dividend with a yield of 0.16%. This makes it attractive for income-focused investors.

Medifast, Inc. (MED) has a return on equity (ROE) of -9.1%. Negative ROE indicates the company is unprofitable.

Medifast, Inc. (MED) had negative free cash flow of $1.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in MED back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

How much would $100/month in MED be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 4, 2026

$0.19vs $0.55+65.5%

$76Mvs $69M+9.9%

Q1 2026

Feb 17, 2026

$0.55vs $0.76+27.6%

$75Mvs $71M+5.2%

Q4 2025

Nov 3, 2025

$0.21vs $0.01-2000.0%

$89Mvs $71M+25.2%

Q3 2025

Aug 4, 2025

$0.04vs $0.30+113.3%

$106Mvs $94M+12.5%

Metric

Dec'17

Dec'18

Dec'19

Dec'20

Dec'21

Dec'22

Dec'23

Dec'24

Dec'25

TTM

Sales/Revenue

301.56M

501M

713.67M

934.84M

1.53B

1.6B

1.07B

602.46M

385.79M

346.1M

Revenue Growth %

9.85%

66.14%

42.45%

30.99%

63.25%

4.75%

-32.94%

-43.8%

-35.96%

-36.31%

Cost of Goods Sold

73.75M

121.1M

176.81M

237.03M

398.49M

458.16M

296.2M

157.84M

110.6M

103.41M

COGS % of Revenue

24.46%

24.17%

24.78%

25.35%

26.11%

28.66%

27.63%

26.2%

28.67%

Gross Profit

227.81M▲ 0%

379.9M▲ 66.8%

536.86M▲ 41.3%

697.82M▲ 30.0%

1.13B▲ 61.6%

1.14B▲ 1.1%

775.85M▼ 32.0%

444.62M▼ 42.7%

275.19M▼ 38.1%

242.7M▲ 0%

Gross Margin %

75.54%

75.83%

75.22%

74.65%

73.89%

71.34%

72.37%

73.8%

71.33%

70.12%

Gross Profit Growth %

10.77%

66.76%

41.32%

29.98%

61.59%

1.14%

-31.97%

-42.69%

-38.11%

Operating Expenses

188.18M

310.84M

445.82M

563.66M

911.36M

955.61M

649.45M

441.75M

289.4M

258.94M

OpEx % of Revenue

62.4%

62.04%

62.47%

60.29%

59.72%

59.78%

60.58%

73.32%

75.02%

Selling, General & Admin

188.18M

310.84M

445.82M

563.66M

911.36M

955.61M

649.45M

441.75M

289.4M

258.94M

SG&A % of Revenue

62.4%

62.04%

62.47%

60.29%

59.72%

59.78%

60.58%

73.32%

75.02%

Research & Development

R&D % of Revenue

Other Operating Expenses

Operating Income

39.63M▲ 0%

69.06M▲ 74.3%

91.04M▲ 31.8%

134.16M▲ 47.4%

216.24M▲ 61.2%

184.81M▼ 14.5%

126.4M▼ 31.6%

2.88M▼ 97.7%

-14.21M▼ 593.8%

-16.25M▲ 0%

Operating Margin %

13.14%

13.78%

12.76%

14.35%

14.17%

11.56%

11.79%

0.48%

-3.68%

-4.69%

Operating Income Growth %

47.56%

74.26%

31.82%

47.36%

61.18%

-14.54%

-31.6%

-97.72%

-593.85%

EBITDA

43.84M

73.5M

95.66M

138.47M

223.05M

195.79M

139.51M

15.59M

-3.71M

-5.28M

EBITDA Margin %

14.54%

14.67%

13.4%

14.81%

14.62%

12.25%

13.01%

2.59%

-0.96%

-1.53%

EBITDA Growth %

35.88%

67.65%

30.16%

44.75%

61.08%

-12.22%

-28.74%

-88.83%

-123.82%

-182.51%

D&A (Non-Cash Add-back)

4.21M

4.43M

4.62M

4.32M

6.81M

10.98M

13.11M

12.71M

10.5M

10.96M

EBIT

39.63M

69.06M

91.04M

134.16M

216.24M

184.76M

126.4M

2.88M

-14.21M

-11.53M

Net Interest Income

558K

1.31M

1.29M

246K

-701K

2.49M

4.8M

5.52M

4.21M

Interest Income

558K

1.31M

1.29M

246K

2.49M

4.8M

5.52M

5.59M

Interest Expense

701K

Other Income/Expense

694K

1.49M

1.32M

106K

-112K

-747K

2.4M

909K

8.57M

8.14M

Pretax Income

40.33M▲ 0%

70.55M▲ 74.9%

92.36M▲ 30.9%

134.26M▲ 45.4%

216.13M▲ 61.0%

184.06M▼ 14.8%

128.8M▼ 30.0%

3.79M▼ 97.1%

-5.64M▼ 248.9%

-8.11M▲ 0%

Pretax Margin %

13.37%

14.08%

12.94%

14.36%

14.16%

11.51%

12.01%

0.63%

-1.46%

-2.34%

Income Tax

12.61M

14.76M

14.45M

31.41M

52.1M

40.49M

29.38M

1.7M

13.03M

11.92M

Effective Tax Rate %

31.26%

20.92%

15.64%

23.39%

24.11%

22%

22.81%

44.78%

-231.12%

-147.03%

Net Income

27.72M▲ 0%

55.79M▲ 101.3%

77.92M▲ 39.7%

102.86M▲ 32.0%

164.03M▲ 59.5%

143.57M▼ 12.5%

99.42M▼ 30.8%

2.09M▼ 97.9%

-18.67M▼ 993.0%

-20.02M▲ 0%

Net Margin %

9.19%

11.14%

10.92%

11%

10.75%

8.98%

9.27%

0.35%

-4.84%

-5.79%

Net Income Growth %

55.43%

101.25%

39.66%

32.01%

59.47%

-12.48%

-30.75%

-97.9%

-992.97%

-186.19%

Net Income (Continuing)

27.72M

55.79M

77.92M

102.86M

164.03M

143.57M

99.42M

2.09M

-18.67M

-20.02M

Discontinued Operations

Minority Interest

EPS (Diluted)

2.29▲ 0%

4.62▲ 101.7%

6.43▲ 39.2%

8.68▲ 35.0%

13.89▲ 60.0%

12.73▼ 8.4%

9.10▼ 28.5%

0.19▼ 97.9%

-1.70▼ 994.7%

-1.82▲ 0%

EPS Growth %

53.69%

101.75%

39.18%

34.99%

60.02%

-8.35%

-28.52%

-97.91%

-994.74%

-181.54%

EPS (Basic)

2.32

4.67

6.62

8.74

14.01

12.82

9.10

0.19

-1.70

Diluted Shares Outstanding

12.09M

12.08M

12.12M

11.85M

11.81M

11.28M

10.92M

10.96M

10.98M

11.01M

Basic Shares Outstanding

11.92M

11.95M

11.77M

11.71M

11.2M

10.88M

10.93M

10.98M

11.01M

Dividend Payout Ratio

55.52%

41.51%

45.43%

51.71%

38.93%

49.89%

73.45%

34.19%

Metric

Dec'17

Dec'18

Dec'19

Dec'20

Dec'21

Dec'22

Dec'23

Dec'24

Dec'25

TTM

Total Current Assets

125.2M

145.52M

154.15M

234.31M

306.87M

222.78M

224.03M

214.4M

201.68M

202.63M

Cash & Short-Term Investments

98.83M

101.03M

92.68M

174.47M

109.54M

87.69M

150.04M

162.34M

167.27M

71.53M

Cash Only

75.08M

81.36M

76.97M

163.72M

104.18M

87.69M

94.44M

90.93M

89.3M

71.53M

Short-Term Investments

23.76M

19.67M

15.7M

10.75M

5.36M

55.6M

71.42M

77.97M

Accounts Receivable

576K

1.01M

1.44M

584K

Days Sales Outstanding

0.7

0.74

0.73

0.23

Inventory

19.33M

38.89M

48.77M

53.39M

180.04M

118.86M

54.59M

42.42M

20.23M

21.4M

Days Inventory Outstanding

95.66

117.21

100.68

82.22

164.91

94.69

67.27

98.1

66.76

83.87

Other Current Assets

-584K

16.33M

16.24M

9.07M

109.7M

Total Non-Current Assets

20.73M

23.91M

40.5M

41.77M

91.46M

93.43M

85.88M

69.81M

55.33M

49.42M

Property, Plant & Equipment

18.61M

19.75M

38.84M

38.14M

80.59M

75.64M

67.11M

48.68M

38.46M

42.56M

Fixed Asset Turnover

16.20x

25.37x

18.37x

24.51x

18.94x

21.13x

15.97x

12.38x

10.03x

8.35x

Goodwill

Intangible Assets

Long-Term Investments

Other Non-Current Assets

2.12M

1.18M

353K

2.94M

6.47M

12.46M

14.65M

9.67M

7.83M

6.85M

Total Assets

145.93M▲ 0%

169.43M▲ 16.1%

194.65M▲ 14.9%

276.08M▲ 41.8%

398.33M▲ 44.3%

316.21M▼ 20.6%

309.91M▼ 2.0%

284.21M▼ 8.3%

257.01M▼ 9.6%

252.05M▲ 0%

Asset Turnover

2.07x

2.96x

3.67x

3.39x

3.83x

5.06x

3.46x

2.12x

1.50x

1.32x

Asset Growth %

20.39%

16.1%

14.89%

41.83%

44.28%

-20.61%

-1.99%

-8.29%

-9.57%

-35.71%

Total Current Liabilities

37.14M

60.32M

79.39M

111.35M

169.83M

140.89M

92.3M

64.16M

42.96M

42.18M

Accounts Payable

13.8M

19.02M

22.61M

36.09M

70.89M

53.12M

39.19M

23.05M

15.07M

Days Payables Outstanding

68.28

57.32

46.67

55.58

64.94

42.32

48.3

53.3

49.72

105.77

Short-Term Debt

4.6M

3.92M

Deferred Revenue (Current)

4.33M

7.61M

8.05M

7.36M

574K

316K

384K

Other Current Liabilities

19.76M

32.77M

13.63M

38.26M

Current Ratio

3.37x

2.41x

1.94x

2.10x

1.81x

1.58x

2.43x

3.34x

4.69x

4.80x

Quick Ratio

2.85x

1.77x

1.33x

1.62x

0.75x

0.74x

1.84x

2.68x

4.22x

4.30x

Cash Conversion Cycle

28.07

60.63

54.74

26.87

-21.91

Total Non-Current Liabilities

208K

1.97M

10.43M

7.49M

26.02M

20.27M

16.13M

9.94M

15.13M

12.18M

Long-Term Debt

6.09M

12.18M

Capital Lease Obligations

10.43M

7.49M

26.02M

20.27M

16.13M

9.94M

6.09M

20.02M

Deferred Tax Liabilities

208K

1.97M

9.04M

Other Non-Current Liabilities

-1.97M

-6.09M

Total Liabilities

37.35M

60.32M

89.82M

118.84M

195.85M

161.17M

108.43M

74.1M

58.09M

54.37M

Total Debt

13.6M

11.16M

32.54M

26.05M

22.01M

16.13M

16.79M

16.1M

Net Debt

-75.08M

-81.36M

-63.37M

-152.56M

-71.64M

-61.64M

-72.43M

-74.8M

-72.52M

-55.43M

Debt / Equity

0.13x

0.07x

0.16x

0.17x

0.11x

0.08x

Debt / EBITDA

0.14x

0.08x

0.15x

0.13x

0.16x

1.03x

-3.05x

Net Debt / EBITDA

-1.71x

-1.11x

-0.66x

-1.10x

-0.32x

-0.31x

-0.52x

-4.80x

10.49x

Interest Coverage

263.57x

Total Equity

108.58M▲ 0%

109.11M▲ 0.5%

104.83M▼ 3.9%

157.25M▲ 50.0%

202.47M▲ 28.8%

155.04M▼ 23.4%

201.48M▲ 30.0%

210.11M▲ 4.3%

198.92M▼ 5.3%

197.68M▲ 0%

Equity Growth %

13.09%

0.48%

-3.92%

50%

28.76%

-23.43%

29.95%

4.28%

-5.33%

-2.84%

Book Value per Share

8.98

9.03

8.65

13.27

17.14

13.75

18.45

19.17

18.11

17.96

Total Shareholders' Equity

108.58M

109.11M

104.83M

157.25M

202.47M

155.04M

201.48M

210.11M

198.92M

197.68M

Common Stock

12K

11K

Retained Earnings

103.76M

131.34M

168.79M

154.35M

190.33M

139.85M

174.65M

176.78M

158.27M

156.15M

Treasury Stock

-30.88M

-63.99M

-5M

-6.4M

Accumulated OCI

-160K

-173K

25K

41K

111K

24K

248K

180K

234K

33K

Minority Interest

Metric

Dec'17

Dec'18

Dec'19

Dec'20

Dec'21

Dec'22

Dec'23

Dec'24

Dec'25

TTM

Cash from Operations

43.24M

60.82M

84.26M

145.2M

94.55M

194.57M

147.66M

24.48M

6.86M

3.72M

Operating CF Margin %

14.34%

12.14%

11.81%

15.53%

6.2%

12.17%

13.77%

4.06%

1.78%

Operating CF Growth %

70.56%

40.66%

38.55%

72.32%

-34.88%

105.8%

-24.11%

-83.42%

-71.96%

-191.38%

Net Income

27.72M

55.79M

77.92M

102.86M

164.03M

143.57M

99.42M

2.09M

-18.67M

-20.02M

Depreciation & Amortization

4.21M

4.43M

4.62M

4.32M

6.81M

10.98M

13.11M

17.4M

14.24M

14.45M

Stock-Based Compensation

4.27M

3.12M

4.52M

6.8M

9.9M

11.05M

8.19M

7.36M

7.64M

3.54M

Deferred Taxes

-623K

-2.69M

1.6M

601K

-3.71M

-924K

1.21M

-7.4M

11.46M

11.44M

Other Non-Cash Items

879K

622K

3.1M

3.72M

5.16M

8.24M

5.46M

14.77M

4.27M

Working Capital Changes

6.78M

-467K

-7.49M

26.9M

-87.65M

21.65M

20.28M

-9.74M

-9.8M

-9.95M

Change in Receivables

815K

122K

-4.06M

297K

Change in Inventory

-1.02M

-18.66M

-9.88M

-4.62M

-126.65M

61.19M

64.27M

12.17M

22.19M

17.96M

Change in Payables

8.01M

15.8M

-37.59M

-35.71M

-34.99M

-23.91M

-19.36M

Cash from Investing

-3.16M

-1.2M

-6.33M

-1.28M

-29.06M

-11.41M

-61.05M

-26.52M

-7.93M

-23.01M

Capital Expenditures

-3.24M

-4.94M

-10.06M

-5.89M

-34.21M

-16.68M

-6.48M

-7.45M

-5.61M

-5.19M

CapEx % of Revenue

1.08%

0.99%

1.41%

0.63%

2.24%

1.04%

0.6%

1.24%

1.46%

1.5%

Acquisitions

81K

196K

3.64M

Investments

Other Investing

81K

196K

95K

3.31M

Cash from Financing

-17.36M

-53.33M

-82.32M

-57.14M

-125.13M

-199.58M

-79.79M

-1.51M

-564K

-902K

Debt Issued (Net)

Equity Issued (Net)

-2.54M

-30.71M

-47.21M

-5.55M

-62.09M

-127.96M

-6.96M

-836K

-369K

-814K

Dividends Paid

-15.39M

-23.16M

-35.4M

-53.19M

-63.86M

-71.62M

-73.02M

-715K

-195K

-88K

Share Repurchases

-2.54M

-30.71M

-47.21M

-5.55M

-62.09M

-127.96M

-6.96M

-836K

-369K

-814K

Other Financing

568K

547K

278K

1.6M

811K

188K

36K

Net Change in Cash

22.64M▲ 0%

6.29M▼ 72.2%

-4.39M▼ 169.8%

86.75M▲ 2076.1%

-59.54M▼ 168.6%

-16.49M▲ 72.3%

6.75M▲ 140.9%

-3.51M▼ 152.0%

-1.63M▲ 53.7%

-20.19M▲ 0%

Free Cash Flow

39.99M▲ 0%

55.88M▲ 39.7%

74.2M▲ 32.8%

139.31M▲ 87.7%

60.34M▼ 56.7%

177.89M▲ 194.8%

141.17M▼ 20.6%

17.02M▼ 87.9%

1.25M▼ 92.7%

-1.47M▲ 0%

FCF Margin %

13.26%

11.15%

10.4%

14.9%

3.95%

11.13%

13.17%

2.83%

0.32%

-0.43%

FCF Growth %

77.96%

39.71%

32.8%

87.74%

-56.69%

194.83%

-20.64%

-87.94%

-92.66%

-110.92%

FCF per Share

3.31

4.63

6.12

11.76

5.11

15.78

12.93

1.55

0.11

-0.13

FCF Conversion (FCF/Net Income)

1.56x

1.09x

1.08x

1.41x

0.58x

1.36x

1.49x

11.71x

-0.37x

0.07x

Interest Paid

Taxes Paid

13.62M

14.61M

17.31M

24.64M

56.76M

37.21M

34.26M

7.1M

Metric

2017

2018

2019

2020

2021

2022

2023

2024

2025

TTM

Return on Equity (ROE)

27.1%

51.26%

72.84%

78.5%

91.2%

80.31%

55.77%

1.02%

-9.13%

-9.68%

Return on Invested Capital (ROIC)

76.35%

169.14%

197.34%

436.12%

239.35%

123.62%

85.23%

1.63%

-8.15%

-9.31%

Gross Margin

75.54%

75.83%

75.22%

74.65%

73.89%

71.34%

72.37%

73.8%

71.33%

70.12%

Net Margin

9.19%

11.14%

10.92%

11%

10.75%

8.98%

9.27%

0.35%

-4.84%

-5.79%

Debt / Equity

0.13x

0.07x

0.16x

0.17x

0.11x

0.08x

Interest Coverage

263.57x

FCF Conversion

1.56x

1.09x

1.08x

1.41x

0.58x

1.36x

1.49x

11.71x

-0.37x

0.07x

Revenue Growth

9.85%

66.14%

42.45%

30.99%

63.25%

4.75%

-32.94%

-43.8%

-35.96%

-36.31%

Medifast, Inc.(MED)Earnings, Financials & Key Ratios

MED Key Insights

✓Strengths

✗Weaknesses

MED Price & Volume

MED Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

MED Recent Earnings

MED Peer Comparison

Compare MED vs Peers

vs HIMS

vs AMZN

Compare Top 5

MED Income Statement

MED Balance Sheet

MED Cash Flow Statement

MED Key Ratios

MED SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

MED Frequently Asked Questions

Medifast, Inc.(MED)Earnings, Financials & Key Ratios

MED Key Insights

✓Strengths

✗Weaknesses

MED Price & Volume

MED Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

MED Recent Earnings

MED Peer Comparison

Compare MED vs Peers

vs HIMS

vs AMZN

Compare Top 5

MED Income Statement

MED Balance Sheet

MED Cash Flow Statement

MED Key Ratios

MED SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

MED Frequently Asked Questions